Novo Interest Income from 2010 to 2026
| NVO Stock | USD 59.43 0.10 0.17% |
Interest Income | First Reported 2019-03-31 | Previous Quarter 5.3 B | Current Value 1.8 B | Quarterly Volatility 1.2 B |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 B, Interest Expense of 2 B or Selling General Administrative of 6.4 B, as well as many indicators such as Price To Sales Ratio of 9.05, Dividend Yield of 0.0115 or PTB Ratio of 18.31. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo | Interest Income | Build AI portfolio with Novo Stock |
Evaluating Novo Nordisk's Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Novo Nordisk AS's fundamental strength.
Latest Novo Nordisk's Interest Income Growth Pattern
Below is the plot of the Interest Income of Novo Nordisk AS over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Novo Nordisk's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
| Interest Income | 10 Years Trend |
|
Interest Income |
| Timeline |
Novo Interest Income Regression Statistics
| Arithmetic Mean | 2,772,352,941 | |
| Geometric Mean | 1,532,954,643 | |
| Coefficient Of Variation | 90.45 | |
| Mean Deviation | 2,309,474,048 | |
| Median | 1,654,200,000 | |
| Standard Deviation | 2,507,488,524 | |
| Sample Variance | 6287498.7T | |
| Range | 5.7B | |
| R-Value | (0.74) | |
| Mean Square Error | 2990026.7T | |
| R-Squared | 0.55 | |
| Significance | 0.0006 | |
| Slope | (369,650,000) | |
| Total Sum of Squares | 100599979.2T |
Novo Interest Income History
Other Fundumenentals of Novo Nordisk AS
Novo Nordisk Interest Income component correlations
Click cells to compare fundamentals
About Novo Nordisk Financial Statements
Novo Nordisk investors utilize fundamental indicators, such as Interest Income, to predict how Novo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Interest Income | 1.7 B | 1.2 B | |
| Net Interest Income | -104.7 M | -109.9 M |
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
| 0.63 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Novo Stock
| 0.84 | AAPL | Apple Inc Aggressive Push | PairCorr |
| 0.7 | T | ATT Inc Earnings Call This Week | PairCorr |
| 0.48 | MSFT | Microsoft | PairCorr |
| 0.32 | MMM | 3M Company | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Novo Nordisk Correlation against competitors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Pharmaceuticals sector continue expanding? Could Novo diversify its offerings? Factors like these will boost the valuation of Novo Nordisk. Anticipated expansion of Novo directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Novo Nordisk data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.27) | Dividend Share 11.65 | Earnings Share 3.76 | Revenue Per Share | Quarterly Revenue Growth 0.051 |
Understanding Novo Nordisk AS requires distinguishing between market price and book value, where the latter reflects Novo's accounting equity. The concept of intrinsic value—what Novo Nordisk's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Novo Nordisk's price substantially above or below its fundamental value.
It's important to distinguish between Novo Nordisk's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Novo Nordisk should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Novo Nordisk's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.